156 related articles for article (PubMed ID: 18058468)
41. Elevated levels of macrophage migration inhibitory factor in the peripheral blood of women with endometriosis.
Morin M; Bellehumeur C; Therriault MJ; Metz C; Maheux R; Akoum A
Fertil Steril; 2005 Apr; 83(4):865-72. PubMed ID: 15820792
[TBL] [Abstract][Full Text] [Related]
42. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
43. Macrophage migration inhibitory factor in zinc-allergic systemic contact dermatitis.
Yanagi T; Kodama K; Yoshihisa Y; Shimizu H; Shimizu T
Cytokine; 2006 Sep; 35(5-6):270-4. PubMed ID: 17070066
[TBL] [Abstract][Full Text] [Related]
44. Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation.
Toubai T; Shono Y; Nishihira J; Ibata M; Suigita J; Kato N; Ohkawara T; Tone S; Lowler KP; Ota S; Tanaka J; Asaka M; Reddy P; Imamura M
Int J Lab Hematol; 2009 Apr; 31(2):161-8. PubMed ID: 18081874
[TBL] [Abstract][Full Text] [Related]
45. [Serum markers for breast and colorectal cancers. Working group reunited by the National Health Agency for Accreditation and Evaluation (NHAAE)].
Mlika-Cabanne N; Bellet D
Gastroenterol Clin Biol; 1998 Apr; 22(4):442-57. PubMed ID: 9762275
[No Abstract] [Full Text] [Related]
46. [Value of serologic markers in the management of colorectal cancer].
Wainstein RC; Milano MC
Acta Gastroenterol Latinoam; 1995; 25(5):309-10. PubMed ID: 8733259
[No Abstract] [Full Text] [Related]
47. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.
Popp J; Bacher M; Kölsch H; Noelker C; Deuster O; Dodel R; Jessen F
J Psychiatr Res; 2009 May; 43(8):749-53. PubMed ID: 19038405
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
[TBL] [Abstract][Full Text] [Related]
49. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
50. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease.
Zou YQ; Lu LJ; Li SJ; Zeng T; Wang XD; Bao CD; Chen SL; Yang CD
Clin Biochem; 2008 May; 41(7-8):519-24. PubMed ID: 18261992
[TBL] [Abstract][Full Text] [Related]
51. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
Mouawad R; Spano JP; Comperat E; Capron F; Khayat D
Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860
[TBL] [Abstract][Full Text] [Related]
52. [The relationship between expression of macrophage migration inhibitory factor and prognosis of breast cancer].
Xu XD; Yao C; Lin Y; Wang LP; Ma LL; Wang SM
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):520-3. PubMed ID: 18649765
[TBL] [Abstract][Full Text] [Related]
53. Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality.
Chuang CC; Wang ST; Chen WC; Chen CC; Hor LI; Chuang AY
Shock; 2007 May; 27(5):503-6. PubMed ID: 17438455
[TBL] [Abstract][Full Text] [Related]
54. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
55. Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis.
Matsumoto K; Maruyama N; Maruyama T; Ohnishi Y; Nonaka S; Inoshita A; Ito K; Kitajima S; Abe M; Satomura A; Fujita T
Clin Exp Immunol; 2005 Feb; 139(2):338-47. PubMed ID: 15654833
[TBL] [Abstract][Full Text] [Related]
56. Quantification of cathepsin D in plasma of patients with malignant melanoma.
Westhoff U; Fox C; Otto FJ
Anticancer Res; 1998; 18(5B):3785-8. PubMed ID: 9854496
[TBL] [Abstract][Full Text] [Related]
57. Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases.
Kibiki GS; van der Ven AJ; Geurts-Moespot A; Shao J; Calandra T; Sweep FC; Dolmans WM
Clin Immunol; 2007 Apr; 123(1):60-5. PubMed ID: 17275414
[TBL] [Abstract][Full Text] [Related]
58. Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers.
Umemori Y; Ohe Y; Kuribayashi K; Tsuji N; Nishidate T; Kameshima H; Hirata K; Watanabe N
Clin Chim Acta; 2010 Dec; 411(23-24):1894-9. PubMed ID: 20655890
[TBL] [Abstract][Full Text] [Related]
59. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
60. Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis.
Krockenberger M; Kranke P; Häusler S; Engel JB; Horn E; Nürnberger K; Wischhusen J; Dietl J; Hönig A
Anticancer Res; 2012 Dec; 32(12):5233-8. PubMed ID: 23225421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
